Harvard Medicine

More... Share to Twitter Share to Facebook
In Circulation

Researchers build a better device for tracking circulating tumor cells.

Technical improvements to a microchip-based device for detecting and analyzing tumor cells in the bloodstream are revealing cellular differences that may reflect a tumor’s aggressiveness and long-term response to treatment. In the March 31 issue of Science Translational Medicine, researchers at Massachusetts General Hospital describe improvements to their CTC chip, which measures levels of circulating tumor cells, or CTCs, in the bloodstream. These advancements may allow better monitoring of how CTC levels react to treatment for prostate cancer and show key biologic properties of the cells.

Comments

Add new comment


Archives